Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies
- 1 December 2017
- journal article
- review article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 17 (12) , 834-851
Abstract
No abstract availableKeywords
This publication has 127 references indexed in Scilit:
- Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta‐analysis and clinical characterizationEuropean Journal of Haematology, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Early detection, prevention and management of cutaneous adverse events due to sorafenib: Recommendations from the Sorafenib Working GroupCritical Reviews in Oncology/Hematology, 2012
- The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapiesJournal of the American Academy of Dermatology, 2011
- PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cellsNature Immunology, 2010
- Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey ResultsOncology, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myelomaJournal of the American Academy of Dermatology, 2006
- Strategies in the Management of Alemtuzumab-Related Side EffectsSeminars in Oncology, 2006
- Respiratory Reovirus 1/L Induction of Intraluminal Fibrosis, a Model of Bronchiolitis Obliterans Organizing Pneumonia, Is Dependent on T LymphocytesThe American Journal of Pathology, 2003